Novavax Inc. ($NVAX) Stock Forecast: Down 5.5% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on developing innovative vaccines to address infectious diseases. The company has been actively involved in the development of a COVID-19 vaccine, among other vaccine candidates.

Why is Novavax Inc. going down?

NVAX stock is down 5.5% on Apr 23, 2026 17:06

• Novavax's stock has been experiencing volatility, with recent bearish movements following two consecutive days of losses.
• The underperformance of Novavax's stock can be attributed to concerns raised by activist investor Himanshu Shah regarding governance, operational shortcomings, and disappointing sales of its Covid vaccine Nuvaxovid.
• Additionally, the call by PETA for Novavax to investigate experiments using monkeys from a controversial lab may have added negative sentiment to the stock.
• Despite these challenges, Wall Street analyst Mayank Mamtani remains optimistic about Novavax's potential, especially driven by upcoming milestones from its Sanofi partnership.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Inc. stock underperforms Tuesday when compared to competitors

Novavax Inc. (NVAX) shares dropped 2.08% on Tuesday, closing at $8.49. This underperformance occurred during a negative trading session for the broader stock market, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing declines. This marks the second consecutive day of losses for Novavax.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-tuesday-when-compared-to-competitors-53f6c47c-0c7ece63bcdb

Novavax Inc. stock underperforms Monday when compared to competitors

Novavax Inc. (NVAX) shares fell by 1.92% to $8.67 on Monday, underperforming in a generally down market where the NASDAQ Composite and Dow Jones Industrial Average also saw declines. The stock closed 27.57% below its 52-week high.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-monday-when-compared-to-competitors-24f1f4ea-8e4b19b2a4ea?mod=mw_quote_news

Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In

Activist investor Himanshu Shah is challenging Novavax's board and executive compensation, citing severe shareholder value destruction and chronic operational shortcomings, including disappointing sales of its Covid vaccine Nuvaxovid and poor cost control. While Wall Street analyst Mayank Mamtani of B. Riley Securities acknowledges some validity in Shah's criticisms, particularly regarding governance, he disagrees with aggressive cost-cutting, emphasizing the importance of preserving talent and partnerships. Mamtani believes Novavax's stock will eventually rise, driven by potential milestones from its Sanofi partnership, despite the current lack of transparency regarding progress.

https://medcitynews.com/2026/04/is-shah-capitals-criticism-of-novavax-fair-a-wall-street-analyst-weighs-in/

Novavax Urged to Probe Studies Using Monkeys From Filthy Lab After PETA Exposé

PETA has called on Novavax to investigate all experiments it commissioned using monkeys from the University of Louisiana’s New Iberia Research Center (NIRC) following a whistleblower video and public records exposé. The exposé revealed disturbing conditions at NIRC, including monkeys housed in unsanitary environments with signs of stress and injury, and evidence that even sick animals were used in experiments by pharmaceutical clients like Pfizer. PETA argues that using compromised animals contaminates data, leading to inaccurate results regarding drug safety and efficacy.

https://www.peta.org/media/news-releases/novavax-urged-to-probe-studies-using-monkeys-from-filthy-lab-after-peta-expose/

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc.'s stock (NVAX) rose 2.31% to $8.84, outperforming major market indices like the NASDAQ Composite and Dow Jones Industrial Average on a strong trading day. The company's stock closed 26.15% below its 52-week high of $11.97. This performance reflects a positive day for Novavax Inc. relative to its competitors.

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-91b8328a-97e2eacc76a6

Trending Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.2% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.1% Today

Centene Corporation ($CNC) Stock Forecast: Up 10.4% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 25.4% Today

Mondelez International Inc. ($MDLZ) Stock Forecast: Up 6.0% Today

Automatic Data Processing Inc. ($ADP) Stock Forecast: Up 6.1% Today

Starbucks Corporation ($SBUX) Stock Forecast: Up 9.1% Today

T-Mobile US Inc. ($TMUS) Stock Forecast: Up 7.5% Today

IDEX Corporation ($IEX) Stock Forecast: Up 7.1% Today

Intel Corporation ($INTC) Stock Forecast: Up 13.7% Today

Novavax Inc. Price History

02.03.2026 - NVAX Stock was down 5.0%

• An investment firm, Shah Capital Management, significantly increased its stake in Novavax during Q4, showing confidence in the company's future despite the recent stock decline. This move could indicate a long-term positive outlook on NVAX.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development brings in a seasoned professional with extensive experience in drug and vaccine development. This change in leadership might signal a strategic shift or renewed focus on research and development efforts.
• The underperformance of Novavax's stock compared to its competitors, despite positive quarterly earnings and revenue growth, suggests that market sentiment or external factors may be influencing investor behavior. This disparity could be a result of broader industry trends or specific company challenges that need addressing.
• The departure of the previous R&D chief after a short tenure and the subsequent internal promotion highlight potential internal restructuring within Novavax. This organizational change could be impacting investor confidence and contributing to the stock's bearish movement.

18.02.2026 - NVAX Stock was down 5.1%

• Despite recent positive developments and analyst support, Novavax Inc. (NVAX) observed a significant 5.56% decrease in its stock price today.
• The increase in institutional investment by Farallon Capital Management LLC, acquiring a notable amount of shares, did not appear to enhance the stock's performance on the current day.
• The varied assessments from analysts, ranging from reaffirmed Buy ratings to optimistic price forecasts, might not have counteracted the broader market sentiment affecting Novavax's stock.
• It seems that notwithstanding the company's impressive earnings report and innovative platform, external market conditions or profit-taking activities could have played a role in today's downward trend for Novavax Inc.

01.03.2026 - NVAX Stock was up 5.0%

• An increase in stake from Shah Capital Management and Novavax's strong quarterly earnings surpassing analyst predictions likely influenced the stock's upward movement.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development may have boosted investor confidence in the company's future innovation efforts.
• Despite trailing behind its competitors recently, positive updates on leadership changes and financial results appear to have overshadowed these concerns and propelled the stock price higher.

19.02.2026 - NVAX Stock was down 7.8%

• Novavax Inc.'s (NVAX) stock closed 5.92% lower at $10.01 today, showing a strong bearish movement.
• The underperformance of NVAX compared to its competitors and the broader market can be attributed to several factors:
• The company is projected to incur losses for the current quarter and fiscal year despite recent positive earnings surprises, impacting investor sentiment.
• Continuous days of losses, including today, may have led investors to take profits after benefiting from the stock's momentum previously.
• The increase in stake by institutional investors like Farallon Capital Management LLC in NVAX could indicate confidence in the company's long-term potential. However, the mixed analyst outlook and the stock closing below its 52-week high reflect ongoing market uncertainty.
• The bearish movement of NVAX today is a result of profit-taking, investor cautiousness due to projected losses, and the influence of broader market trends on the stock's performance.

20.02.2026 - NVAX Stock was up 5.5%

• Novavax (NVAX) stock saw a significant 5.56% surge to $10.64 today.
• This growth is linked to the company's recent earnings report surpassing expectations, with earnings of $0.11 EPS beating predictions of -$0.66 and a substantial 66.6% year-over-year revenue increase to $136.4 million.
• Although there have been days where the stock didn't perform as well as competitors and the overall market, positive investor sentiment regarding Novavax's earnings surprises and company interest contributed to today's rise.
• Investors are cautiously observing Novavax's high 5.93 debt-to-equity ratio and the average "Hold" rating from brokerages, signaling a wary outlook despite recent positive developments.

30.02.2026 - NVAX Stock was down 5.1%

• Dr. Robert Walker's appointment as the new Executive Vice President and Head of Research & Development at Novavax was received positively, demonstrating the company's commitment to advancing its R&D efforts.
• Despite strong financial results in Q4 2025, the market's bearish reaction may be linked to uncertainties regarding the leadership transition and potential impacts on future vaccine projects.
• Trade ideas and analyses for Novavax on TradingView revealed a mix of bullish and bearish sentiments, highlighting differing investor opinions on the stock's future performance.
• Some traders showed optimism based on technical indicators and fundamental catalysts such as licensing agreements, while others adopted a cautious stance due to stock volatility and the importance of effective risk management strategies.

24.02.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed minimal growth but lagged behind the overall market performance, hinting at negative investor sentiment.
• Regulatory filings by the company disclosed significant occurrences such as payments for milestones, FDA nods, and financial operations, potentially impacting market perception.
• Challenges persist for Novavax, including consecutive days of losses and weaker performance relative to industry peers, raising investor apprehensions.
• With a neutral "Hold" rating from brokerage firms, surpassing earnings, and heightened institutional investor interest, the stock displays a mixed outlook, prompting cautious market behavior.

23.03.2026 - NVAX Stock was down 5.5%

• Novavax's stock has been experiencing volatility, with recent bearish movements following two consecutive days of losses.
• The underperformance of Novavax's stock can be attributed to concerns raised by activist investor Himanshu Shah regarding governance, operational shortcomings, and disappointing sales of its Covid vaccine Nuvaxovid.
• Additionally, the call by PETA for Novavax to investigate experiments using monkeys from a controversial lab may have added negative sentiment to the stock.
• Despite these challenges, Wall Street analyst Mayank Mamtani remains optimistic about Novavax's potential, especially driven by upcoming milestones from its Sanofi partnership.

08.03.2026 - NVAX Stock was up 5.6%

• A major investor in Novavax, Shah Capital, has initiated efforts to revamp the company's board and leadership, citing concerns about previous missteps and lower-than-expected vaccine sales.
• Criticisms from this investor regarding Novavax's direction and management have prompted a shareholder movement, increasing pressure on the company to make changes.
• Shah Capital's decision to vote against board nominees and executive pay has hinted at potential management changes within Novavax, resulting in a rise in the stock's value.
• Investor enthusiasm for Shah Capital's proposals for strategic changes, cost reductions, and a possible company sale has led to a positive market response, indicating optimism for a revitalization in Novavax's performance and shareholder interests.

15.03.2026 - NVAX Stock was up 5.4%

• An increased stake by SHAH CAPITAL MANAGEMENT in Novavax Inc demonstrates confidence in the company's vaccine development potential, despite concerns about overvaluation and poor growth indicators.
• Novavax's pivot towards a diversified pipeline of vaccines, utilizing its protein-based platform and Matrix-M adjuvant technology, is viewed favorably by investors for sustainable growth and reduced reliance on single products.
• The revenue breakdown of the company emphasizes the strong performance of its "Innovative Vaccines" segment, signaling a positive outlook for its vaccine development efforts.
• Despite recent stock price underperformance compared to peers, the long-term value of Novavax and its potential for FDA approvals, successful clinical readouts, and strategic partnerships are driving investor interest and the current bullish movement in the market.

10.03.2026 - NVAX Stock was down 5.2%

• Novavax's stock had a bearish movement despite outperforming competitors and the broader market in the past few days, indicating a shift in investor sentiment.
• The increase in price target to $18 from $16 and maintaining a Buy rating did not seem to positively impact the stock, suggesting other factors are at play.
• Criticisms regarding Novavax's strategy, calls to slash costs, and overhaul the board of directors might have contributed to the bearish movement as investors react to uncertainties surrounding the company's future direction.
• The lackluster Q4 earnings, projected revenue decline, and cash flow concerns highlighted in the analysis post-earnings could have further fueled the negative market sentiment towards Novavax, leading to the bearish movement.

27.02.2026 - NVAX Stock was down 5.5%

• The bearish movement in NVAX stock can be attributed to:
• Overall market underperformance: NVAX's decline occurred during a negative trading session for major indexes like the NASDAQ Composite and Dow Jones Industrial Average.
• Renewed scrutiny and volatility in the biotech sector: Investor attention on Novavax's pipeline updates and financial health amidst post-COVID revenue declines may have added pressure on the stock.
• Technical analysis signals: Algorithmic analysis highlighting a mid-channel oscillation pattern and divergent sentiment across different time horizons might have influenced traders' decisions.
• Despite a brief gain on Monday breaking a losing streak, NVAX continues to struggle to outperform the broader market, indicating ongoing challenges and uncertainties surrounding the company's future prospects.